Advanced searches left 3/3

Zidovudine - Europe PMC

Summarized by Plex Scholar
Last Updated: 08 August 2022

* If you want to update the article please login/register

Solid dispersions based on chitosan/hypromellose phthalate blends to modulate pharmaceutical properties of zidovudine.

Zidovudine has been widely used alone or in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus infections. The construction of mucoadhesive solid dispersions based on chitosan and hypromellose phthalate was considered as a potential way to modify AZT's physical and pharmaceutical characteristics in this study. SDs as a carrier platform for AZT is a novel idea for modulating the physico-chemical, mucoadhesive, and release characteristics of the drug, which has been a cost-effective, low-cost, and scalable technology suggested for manufacturing SDs as a carrier platform for AZT.

Source link: https://europepmc.org/article/MED/35786299


Zidovudine multi-combos with last-line fosfomycin, ceftazidime-avibactam, colistin and tigecycline against Multi-Drug Resistant Klebsiella pneumoniae

Zidovudine was identified in a previous drug repurposing synergy screening as a fosfomycin enhancer against Klebsiella pneumoniae ATCC 13883. By the checkerboard assay, we established the zidovudine/fosfomycin combination against a series of 12 MDR K. pneumoniae isolates. The correlation between zidovudine and fosfomycin was 83. 3 percent in CBA synergy. With potent killing activities, TKA reported error confirmation rates of 83. 3% for zidovudine/fosfomycin, 75% for zidovudine/colistin, 75% for zidovudine/colistin, and 66. 6 percent for zidovudine/colistin. More than 45% for meropenem/colistin, 33. 3 percent for meropenem/colistin, 75% for fosfomycin/colistin, and 66. 6% for fosfomycin/tigecycline with lower bactericidal activity than zidovudine-based combinations had synergy rates of 42. 6% for fosfomycin/colistin, 33. 6% for fosfomycin/colistin The triple zidovudine/fosfomycin/colistin combination had behaviours similar to fosfomycin/colistin and fosfomycin/zidovudine. Zidovudine, in vitro mixtures with existing antibiotics against MDR K. pneumoniae, is an effective partner, particularly with ceftazidime-avibactam, fosfomycin, or colistin. To clarify the clinical efficacy of zidovudine as a repurposed drug in antibacterial therapy, further research is needed.

Source link: https://europepmc.org/article/PPR/PPR494855

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions